Moreover, breast cancers may independently overexpress a molecule called the HER2/neu oncogene and these HER2/neu + tumors are amenable to treatment with targeted biological agents such as trastuzumab, with improvement of survival (1, 3, 4). This evidence concerns the gene ERBB2 and breast carcinoma.